Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride and dutasteride may cause depression and suicidal thoughts.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

This pilot study found that using skin patting with iontophoresis to deliver dutasteride gel significantly improved hair density, shaft diameter, and pull test scores in men and postmenopausal women with treatment-resistant androgenetic alopecia, with participants reporting high satisfaction and no adverse events.

This study found that using a pharmacogenetic panel with 26 SNPs can improve treatment outcomes for androgenetic alopecia, as overall response rates to minoxidil, finasteride, and dutasteride were high, and specific genetic markers predicted poor responses to these drugs.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study developed a bifunctional sodium hyaluronate microneedle patch incorporating glycyrrhizin-loaded dutasteride micelles and mesoporous polydopamine nanoparticles, which effectively inhibited DHT and reduced ROS in hair follicle cells, resulting in significantly accelerated hair growth in vitro and in vivo.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

In this study, analysis of FDA adverse event reports revealed that topical finasteride was associated with fewer post-finasteride syndrome-like adverse events than oral finasteride, but many reports lack critical data, suggesting caution in attributing causality.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This study found that ethosomes containing 30% ethanol slightly improved the targeting of dutasteride to hair follicles in vitro, with a higher targeting factor compared to dried ethosomes and controls after 24 hours on porcine skin.

This review found that mesotherapy could improve hair density and reduce hair fall in androgenetic alopecia, especially when combined with other treatments, but lacks standardized protocols and long-term safety data.

This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.

Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.

This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.

This study found that long-term use of dutasteride in men taking it for androgenetic alopecia may lead to persistent decreases in semen volume and sperm motility, potentially impacting fertility, with significant impairment observed after 17.8 to 20.3 months of treatment.

Five monthly sessions of minoxidil-dutasteride-copper peptide tattooing significantly improve hair regrowth in men with androgenetic alopecia.

This article reviews current therapeutic strategies for frontal fibrosing alopecia and discusses the potential of oral dutasteride as a first-line treatment, emphasizing the need for more clinical trials.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This review examines male androgenetic alopecia and reports no new clinical results, offering insights to aid dermatologists in making informed therapeutic decisions.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

In this study, researchers developed and evaluated a topical dutasteride gel for treating male pattern baldness, finding that a formulation with 10% garlic extract showed the most promising results in promoting faster hair growth compared to other formulations tested.

In this retrospective cohort study, researchers found no significant difference between finasteride and dutasteride in terms of reducing prostate volume or adverse effects among patients with benign prostatic hyperplasia, although both drugs improved lower urinary tract symptoms over one year by reducing prostate volume.

This review discusses the current therapies for androgenic alopecia, emphasizing topical formulations like minoxidil and finasteride and exploring the potential of dutasteride-loaded nanocarriers for targeting hair follicles to minimize systemic side effects from oral treatment.